- •CONTENTS
- •Contributors
- •Preface
- •I Components of Angiogenic Cascades
- •1. Introduction and Historical Perspective
- •2. The Semaphorins
- •3. The Plexin Receptor Family
- •4. The Neuropilins
- •5. Vascular Endothelial Growth Factors and Their Receptors
- •6. Signal Transduction by Neuropilins
- •7. The Role of the Neuropilins in the Regulation of Vasculogenesis and Angiogenesis
- •8. Modulation of Angiogenesis by Semaphorins that Bind Directly to Plexins
- •Acknowledgments
- •References
- •1. Introduction
- •1.1. Eph receptor domain structure
- •1.2. The ephrin domain structure
- •2. Effects on Vascular Cell Behavior and Signaling Pathways
- •2.1. Ephrin-A1 and EphA2
- •2.2. Ephrin-A1 and EphA4
- •2.3. Ephrin-B and EphB
- •2.3.1. EphB forward signaling
- •2.3.2. Ephrin-B reverse signaling
- •2.4. Crosstalk with other angiogenic pathways
- •3. Endothelial Cell Fate
- •4. Angiogenic Remodeling of Embryonic Blood Vessels
- •4.1. Ephrin-A1 and EphA receptors
- •4.2. EphB4 and Ephrin-B2
- •4.3. Other EphB receptors and Ephrin-Bs
- •5. Lymphatic Vessels
- •6. Adult Vasculature
- •6.1. Quiescent vasculature
- •6.2. Physiological angiogenesis
- •6.3. Inflammation and wound healing
- •6.4. Tumor angiogenesis
- •6.4.1. Ephrin-A1 and EphA2
- •6.4.2. Ephrin-B2 and EphB4
- •8. Perspectives
- •Acknowledgments
- •References
- •1. Introduction
- •2. Molecular Mechanisms
- •3. Role in Vascular Development
- •4. FGFs in Tumor Angiogenesis
- •5. Role of FGFs in Developmental and Tumor Lymphangiogenesis
- •7. Conclusion
- •Acknowledgments
- •References
- •1. The NPY System
- •2. NPY as a Growth Factor for Vascular Cells
- •3. DPPIV: A Molecular Switch of the NPY Angiogenic System
- •4. Downstream Mediators of NPY Actions
- •5. NPY in Revascularization of Ischemic Tissues
- •6. NPY in Wound Healing
- •7. NPY in Adipose Tissue Growth and Obesity
- •8. NPY in Retinopathy
- •10. NPY in Tumor Angiogenesis
- •11. NPY-Mediated Angiogenesis and Neurogenesis
- •References
- •1. Introduction
- •2. Historical Perspective
- •3.1. The HSPG core proteins
- •3.2. The structure of the HS chain
- •3.3. The biosynthesis of HS
- •3.4. The post-synthetic processing of HSPGs
- •4. Evolution of HSPGs
- •5. HSPGs in Development
- •6. HSPG Modulation of Ligand-Receptor Interactions
- •6.2. HSPG co-receptors confer unique regulatory properties
- •6.2.1. Co-receptors engender stoichiometric control of signaling
- •6.2.2. The effects of glycanation
- •6.2.3. HS sequence motifs regulate signaling
- •7. HSPGs Enable Global Control of EC Phenotype
- •8. Future Therapeutic Directions
- •9. Conclusions
- •References
- •II Angiogenic Regulators
- •1. Introduction: Blood Vessels and Nerves Use Similar Guidance Cues
- •2. Semaphorin Signaling
- •2.1. Neuropilins
- •2.2. Plexins
- •3. Ephrins and Eph Signaling
- •3.1. Forward signaling
- •3.2. Reverse signaling
- •4. Netrin and Slit Signaling
- •5. Open Questions
- •References
- •1. Oxygen Homeostasis: Phylogeny, Ontogeny, Physiology, and Pathobiology
- •5. Control of Angiogenesis and Arteriogenesis by HIF-1
- •6. Control of Tumor Angiogenesis by HIF-1
- •References
- •1. Introduction
- •2. Reactive Oxygen Species (ROS) in the Vasculature
- •3. ROS and Angiogenesis
- •4. NAD(P)H Oxidase: A Major Source of ROS in the Vasculature
- •5. Role of NAD(P)H Oxidase in Angiogenesis
- •6. ROS as Signaling Molecules in Angiogenesis
- •8. Conclusion
- •References
- •1. Introduction
- •2. Assessing Coronary Angiogenesis and Arteriogenesis
- •3. Pressure Overload-Induced Hypertrophy
- •4. Volume Overload-Induced Cardiac Hypertrophy
- •5. Thyroxine-Induced Hypertrophy
- •6. Hypoxia-Induced Hypertrophy
- •7. Exercise-Induced Hypertrophy
- •8. Myocardial Infarction-Induced Hypertrophy
- •9. Modulators of Angiogenesis During Hypertrophy
- •10. Stimuli of Angiogenesis During Hypertrophy
- •11. Summary
- •References
- •1. Introduction
- •2. Coronary Resistance
- •3. Regulation of Coronary Microvascular Tone
- •3.1. Intrinsic and extrinsic vasomotor control
- •3.2. Role of the endothelium
- •3.3. Role of metabolism and autoregulation
- •3.4. Flow-induced dilation
- •3.5. Neurohumoral influence on microcirculation
- •3.6. Intrinsic myogenic tone
- •3.7. Impact of extravascular and humoral factors on the coronary microcirculation
- •3.8. Role of venules in coronary resistance
- •4. Endothelial Factors in Vascular Growth and Response to Injury
- •5. Impact of Disease States on Coronary Circulation
- •6. The Coronary Microcirculation in Hypertophic States
- •7. Summary
- •References
- •III Clinical Applications
- •1. Kinase Inhibition and Tumor Angiogenesis
- •2. Major Angiogenesis Factors and Receptors
- •2.1. VEGF signaling
- •3. Further Angiogenesis-Related Signaling
- •4. Need for Selectivity of Anti-Angiogenic Kinase Inhibitors
- •5. Kinase Inhibitors in Clinical Development
- •5.1. BAY 43-9006 (Sorafenib)
- •5.2. PTK/ZK (Vatalanib)
- •5.3. SU11248 (Sunitinib)
- •5.9. BIBF 1120
- •5.10. Chir-258
- •5.12. SU5416 (Semaxinib)
- •6. Challenges and Future Directions
- •Acknowledgments
- •References
- •1. Introduction
- •2. Concepts and Rationales
- •3. Strategy
- •4. Clinical Trials
- •4.1. Growth factor-based, angiogenic approach
- •4.2. Cell therapy-based, vasculogenic and paracrine approach
- •5. Issues Regarding Current Strategy
- •5.1. Choice of biological agent
- •5.2. Pharmacokinetics and delivery mode
- •5.3. Monitoring of neovascularization
- •5.4. Study design
- •6. Emerging Concepts of Therapeutic Angiogenesis
- •6.1. Neovascularization responsiveness
- •6.2. Genetic determination of neovascularization
- •7. Future Prospective
- •8. Summary
- •References
- •1. Hepatocyte Growth Factor in Cardiovascular System
- •2. HGF Signaling in Endothelial Cells
- •3. Angiogenic Therapy for Ischemic Peripheral Arterial Diseases
- •4. Clinical Trial in PAD
- •5. HGF Gene Therapy for Myocardial Ischemia
- •6. HGF Gene Therapy for Restenosis After Angioplasty
- •7. Next Five Years Perspective — Future Direction of HGF Therapy
- •Acknowledgments
- •References
- •1. Endothelial Nitric Oxide in Health and Disease
- •1.1. Nitric oxide synthases
- •1.2. Physiological role of endothelial NO (“EDNO”)
- •1.3. Endothelial NO-deficiency in cardiovascular diseases
- •1.4. Therapeutic restoration of endothelial NO production in cardiovascular diseases
- •2. Nitric Oxide and Angiogenesis
- •2.2. Tumor angiogenesis and NO
- •2.3. Evidence in cultured endothelial cells and in rabbit cornea
- •2.4. Role of NO in post-ischemic revascularization
- •2.6. Molecular mechanisms
- •3. NOS Gene Transfer
- •3.1. Gene delivery vectors
- •3.2. NOS-III gene transfer
- •3.3. NOS-II gene transfer
- •4.1. Impaired angiogenesis and arteriogenesis in patients with critical limb ischemia
- •4.2.1. NOS-III-KO mice
- •4.2.2. NOS-III transgenic mice
- •4.2.3. Wild-type NOS-III gene transfer in normal rats
- •4.5.1. Plasmid delivery of the NOS1177D gene
- •4.5.2. Adenoviral delivery of the NOS1179D gene
- •6. Conclusions
- •Acknowledgments
- •References
- •Index
300 B. Ramlawi et al.
cells.51 In addition, complement fragment C5a causes neutophil adherence in venules but not in arterioles, suggesting that different mechanisms mediate neutrophil-endothelial adherence in the two vessel types.52
4.Endothelial Factors in Vascular Growth and Response to Injury
It is important to identify the role of nitric oxide and nitric oxide-related factors in vascular physiology and pathology as summarized in Fig. 10. Nitric oxide inhibits vascular smooth muscle proliferation via apoptosis. Animal models have shown that treatment with L-nitroarginine methyl ester (L-NAME), and inhibitor of NO formation, markedly increases neointimal development following vascular injury.53 Also,
Fig. 10. Schematic representation of endothelium and vascular smooth muscle demonstrating the multifaceted roles of nitric oxide released from the endothelium in the modulation of vascular function, structure, and the response to injury. cGMP, cyclic guanidine monophosphate. (Adapted from Ref. 71.)
Regulation of Coronary Vascular Tone and Microvascular Physiology |
301 |
local transfection with the eNOS cDNA reduces the intimal proliferation which follows balloon injury.54 The vascular response to injury is enhanced in mice deficient in eNOS.55,56 Thus, NO• and cyclic GMP elevating agents inhibit the growth of fibroblasts and vascular smooth muscle. This effect of NO on vascular smooth muscle growth is mediated by cGMP and can be mimicked by atrial natriuretic factor.56,57
NO plays an important role in supporting the process of angiogenesis; since endothelial cells do not seem to be sensitive to the growth inhibitory effects of nitric oxide. In fact, vascular endothelial growth factor (VEGF) actions during angiogenesis are mediated by NO (see Chapter 14). Endothelial cells in the proliferative phase have a six-fold increase in eNOS expression compared to confluent ones and eNOS knockout mice have little VEGF activity.19 During the vascular injury response, this feed-forward condition promotes vascular growth — since while endothelial cells are proliferating to form new blood vessels, the high levels of NO promote tube formation. Similarly, in response to the denudation injury, proliferating endothelial cells increase NO production during the growth period to compensate for the lack of endothelial cells in the denuded area while also decreasing platelet adhesion and vascular smooth muscle proliferation in that same area. Moreover, endothelial progenitor cells (EPC) from the bone marrow play a role in repair of denuded vessels as well as angiogenesis. While not completely elucidated, circulating EPCs seem to vary in quantity from one patient to the next depending on the presence of common risk factors such as diabetes (decreased amount) or lipid-lowering drugs such as HMG-Co A reductase inhibitors (increased amount).
5. Impact of Disease States on Coronary Circulation
Coronary microvascular homeostasis may be adversely affected in disease states through variation in their diameter, quantity or responsiveness to humoral factors. Vasomotor tone reliant on endothelial function is particularly vulnerable to pathology such as atherosclerosis, hyperlipidemia, diabetes or the aging process. This mechanism is highlighted in Fig. 11. The mechanisms underlying these abnormal endothelium-dependent responses are likely multifactorial. Factors responsible include abnormalities of G-protein signaling, resulting
302 B. Ramlawi et al.
Fig. 11. Reduced production/bioreactivity of endothelium-derived NO in the setting of atherosclerosis, diabetes, and many other pathological conditions. ADMA, asymmetrical dimethylarginine, acts as an antagonist of L-arginine. Superoxide (O•2−) and other oxygen free radicals may interfere with NO availability in conditions of increased oxidant stress. OONO•, peroxynitrite radical may inhibit tetrahydrobiopterin (BH4), a cofactor for nitric oxide synthase (NOS). (Adapted from Ref. 71.)
in reduced activation of eNOS in response to endothelial cell receptor activation, an alteration of levels of the critical co-factor for eNOS tetrahydrobiopterin (BH4), and an overproduction of the asymmetric dimethylarginine (ADMA) which acts as an antagonist for the eNOS substrate L-arginine. It has been shown that oxidative stress (via increased production of vascular superoxide — O•2−) is particularly increased in the presence of common coronary risk factors. Such an increase in oxidative stress will cause a reduction in endotheliumdependent vasodilatation.
It is currently well proven that diseases that affect endothelialdependent vascular dilation impact the coronary microcirculation in addition to the larger vessels. Previous experiments have demonstrated that in coronary microvessels from monkeys fed a high cholesterol diet for 18 months, relaxations to acetylcholine, bradykinin, and the calcium ionophore A23187, were dramatically impaired or even produced paradoxical constrictions.58 Similar findings have been made in other
Regulation of Coronary Vascular Tone and Microvascular Physiology |
303 |
animal models of diet-induced atherosclerosis. Subsequent studies performed using in vivo techniques showed that vasoconstriction caused by serotonin and ergonovine (both known to be modulated by the endothelium) was markedly enhanced in the coronary microcirculation of hypercholesterolemic monkeys.59 These findings are impressive because the coronary microcirculation is spared from the development of overt atherosclerosis. Therefore, in the setting of a risk factor for atherosclerosis, “endothelial dysfunction” occurs leading to an abnormal vascular response. Subsequently, diminished flow responses to acetylcholine have been demonstrated in humans with hypercholesterolemia that were restored with reduction of cholesterol levels.60 Similar observations have been made in either humans or experimental models of hypertension,61 ischemia-reperfusion52,62 and diabetes.63 It has also been suggested that this endothelial dysfunction plays a role in the development of clinical symptoms despite normal coronary anatomy. Table 2 summarizes studies demonstrating the effects hypercholesterolemia on coronary arterial microvessels.
Impaired endothelial-dependent vasodilation also has been linked to increased cardiovascular events. The loss of NO in cardiovascular disease not only leads to a decrease in vasodilation, but also predisposes to atherosclerotic lesion formation and vascular smooth muscle proliferation. NO also has antioxidant properties and prevents adhesion molecule expression by endothelial cells. An example of relevance to the clinical setting is the endothelial changes in the coronary microcirculation following cardioplegic arrest and cardiopulmonary bypass during cardiac surgery.64 In this setting, endothelial dysfunction persists for some time after cardiopulmonary bypass, and normalizes thereafter. This has important clinical implications, since it is common for patients undergoing coronary artery bypass grafting, with seemingly complete coronary revascularization, to exhibit signs of myocardial ischemia during the hours following surgery — likely caused by endothelial dysfunction.
Collateral vessels within the coronary circulation are particularly important in coronary disease. These allow for normal resting perfusion to a region of the myocardium that is served by an occluded vessel, albeit at a lower perfusion pressure. However, the coronary arterioles
Table 2. Functional alteration of coronary arterial microvessels by hypercholesterolemia.
|
|
|
|
Microvascular functional |
Ref. no. |
Material |
Cholesterol feeding |
Experiments |
Vessel size |
alteration |
|
|
|
|
|
|
|
Rabbit |
0.5% or 2% |
In vitro |
290 µm in |
Reduced dilation to ACh, |
78 |
|
cholesterol, |
|
mean value |
ADP |
|
|
10–12 weeks |
|
|
|
|
Monkey |
0.7% cholesterol, |
In vitro |
12–220 µm |
Enhanced contraction to |
58 |
|
18 months |
|
|
ACh; reduced dilation to |
|
|
|
|
|
BK, A23187 |
|
Monkey |
0.8% cholesterol, |
In vivo |
< 190 – |
Increase in microvascular |
59 |
|
18 months |
microvascular |
350µm |
resistance to 5-HT |
|
|
|
pressure |
|
|
|
Monkey |
0.7% cholesterol, |
In vitro |
100–200 µm |
Reduced dilation to ADP, |
79 |
|
8–12 weeks or |
|
|
5-HT; paradoxical |
|
|
18–80 weeks |
|
|
constriction to thrombin; |
|
|
|
|
|
hyperconstriction to TXA, |
|
|
|
|
|
analogue |
|
Pig |
3% cholesterol, |
In vitro |
30–70 µm |
Reduced dilation to flow, |
80 |
|
16–20 weeks |
|
|
ADP, |
|
|
|
|
300µm |
5-HT histamine, BK |
|
Monkey |
0.7% cholesterol, |
In vivo |
Enhanced constriction to |
81 |
|
|
25 months |
|
|
5-HT in mean value |
|
Pig |
2% cholesterol, |
In vitro |
300–480 µm |
Enhanced constriction to |
82 |
|
10–13 weeks |
|
|
HT-1, S6c in mean value |
|
Human |
CAD patients |
In vitro |
57–183 µm |
Reduced dilation to HGF, |
83 |
|
|
|
|
VEGF |
|
CAD, Coronary arterial disease; S6c, semafotoxin, ETB receptor agonist.
Source: Adapted from Ref. 2.
.al et Ramlawi .B 304
